Skip to main content
Top
Published in: Critical Care 5/2013

Open Access 01-10-2013 | Research

Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: a prospective study with the LiMAx test

Authors: Magnus F Kaffarnik, Johan F Lock, Hannah Vetter, Navid Ahmadi, Christian Lojewski, Maciej Malinowski, Peter Neuhaus, Martin Stockmann

Published in: Critical Care | Issue 5/2013

Login to get access

Abstract

Introduction

Liver dysfunction can derive from severe sepsis and might be associated with poor prognosis. However, diagnosis of septic liver dysfunction is challenging due to a lack of appropriate tests. Measurement of maximal liver function capacity (LiMAx test) has been successfully evaluated as a new diagnostic test in liver resection and transplantation. The aim of this study was to evaluate the LiMAx test during sepsis in comparison to biochemical tests and the indocyanin green test (ICG-PDR).

Methods

We prospectively investigated 28 patients (8 female and 20 male, age range 35 to 80 years) suffering from sepsis on a surgical ICU. All patients received routine resuscitation from septic shock (surgery, fluids, catecholamines, antibiotic drugs). The first LiMAx test and ICG-PDR were carried out within the first 24 hours after onset of septic symptoms, followed by day 2, 5 and 10. Other biochemical parameters and scores determining the severity of illness were measured daily. Clinical outcome parameters were examined after 90 days or at the end of treatment. The population was divided into 2 groups (group A: non-survivors or ICU length of stay (ICU-LOS) >30 days versus group B: survivors and ICU-LOS <30 days) for analysis.

Results

Epidemiological baseline characteristics of both groups were similar. Group A patients had significant lower LiMAx and ICG-PDR values than patients in group B. Determination of ICG-PDR by finger probe failed in 14.3% of tests due to insufficient peripheral pulses. Respiratory, renal and hepatic dysfunction (LiMAx and ICG-PDR) were associated with prolonged ICU-LOS. Only LiMAx <100 μg/kg/h and respiratory dysfunction were associated with increased mortality. For LiMAx <100 μg/kg/h receiver operating characteristic-analysis revealed a 100% sensitivity and 77% specificity for death.

Conclusions

Sepsis-related hepatic dysfunction can be diagnosed early and effectively by the LiMAx test. The extent of LiMAx impairment is predictive for patient morbidity and mortality. The sensitivity and specificity of the LiMAx test was superior to that of ICG-PDR regarding the prediction of mortality.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brun-Buisson C: The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26: S64-S74. 10.1007/s001340051121CrossRefPubMed Brun-Buisson C: The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26: S64-S74. 10.1007/s001340051121CrossRefPubMed
2.
go back to reference Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J: Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144–002). Crit Care Med 2004, 32: 1-12. 10.1097/01.CCM.0000105118.66983.19CrossRefPubMed Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J: Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144–002). Crit Care Med 2004, 32: 1-12. 10.1097/01.CCM.0000105118.66983.19CrossRefPubMed
3.
go back to reference Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR: Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine 2003, 82: 392-406. 10.1097/01.md.0000101573.54295.bdCrossRefPubMed Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR: Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine 2003, 82: 392-406. 10.1097/01.md.0000101573.54295.bdCrossRefPubMed
4.
go back to reference Brienza N, Dalfino L, Cinnella G, Diele C, Bruno F, Fiore T: Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med 2006, 32: 267-274. 10.1007/s00134-005-0023-3CrossRefPubMed Brienza N, Dalfino L, Cinnella G, Diele C, Bruno F, Fiore T: Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med 2006, 32: 267-274. 10.1007/s00134-005-0023-3CrossRefPubMed
5.
go back to reference Harbrecht BG, Zenati MS, Doyle HR, McMichael J, Townsend RN, Clancy KD, Peitzman AB: Hepatic dysfunction increases length of stay and risk of death after injury. J Trauma 2002, 53: 517-523. 10.1097/00005373-200209000-00020CrossRefPubMed Harbrecht BG, Zenati MS, Doyle HR, McMichael J, Townsend RN, Clancy KD, Peitzman AB: Hepatic dysfunction increases length of stay and risk of death after injury. J Trauma 2002, 53: 517-523. 10.1097/00005373-200209000-00020CrossRefPubMed
6.
go back to reference Kramer L, Jordan B, Druml W, Bauer P, Metnitz PG: Incidence and prognosis of early hepatic dysfunction in critically ill patients – a prospective multicenter study. Crit Care Med 2007, 35: 1099-1104. 10.1097/01.CCM.0000259462.97164.A0CrossRefPubMed Kramer L, Jordan B, Druml W, Bauer P, Metnitz PG: Incidence and prognosis of early hepatic dysfunction in critically ill patients – a prospective multicenter study. Crit Care Med 2007, 35: 1099-1104. 10.1097/01.CCM.0000259462.97164.A0CrossRefPubMed
7.
go back to reference Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Schoniger-Hekele M, Madl C, Schenk P: Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med 2011, 37: 1302-1310. 10.1007/s00134-011-2248-7CrossRefPubMed Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Schoniger-Hekele M, Madl C, Schenk P: Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med 2011, 37: 1302-1310. 10.1007/s00134-011-2248-7CrossRefPubMed
8.
go back to reference Sakka SG: Assessing liver function. Curr Opin Crit Care 2007, 13: 207-214. 10.1097/MCC.0b013e328012b268CrossRefPubMed Sakka SG: Assessing liver function. Curr Opin Crit Care 2007, 13: 207-214. 10.1097/MCC.0b013e328012b268CrossRefPubMed
9.
go back to reference Kimura S, Yoshioka T, Shibuya M, Sakano T, Tanaka R, Matsuyama S: Indocyanine green elimination rate detects hepatocellular dysfunction early in septic shock and correlates with survival. Crit Care Med 2001, 29: 1159-1163. 10.1097/00003246-200106000-00014CrossRefPubMed Kimura S, Yoshioka T, Shibuya M, Sakano T, Tanaka R, Matsuyama S: Indocyanine green elimination rate detects hepatocellular dysfunction early in septic shock and correlates with survival. Crit Care Med 2001, 29: 1159-1163. 10.1097/00003246-200106000-00014CrossRefPubMed
10.
go back to reference Sakka SG, Reinhart K, Meier-Hellmann A: Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002, 122: 1715-1720. 10.1378/chest.122.5.1715CrossRefPubMed Sakka SG, Reinhart K, Meier-Hellmann A: Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002, 122: 1715-1720. 10.1378/chest.122.5.1715CrossRefPubMed
11.
go back to reference Kortgen A, Lindemann W, Bauer M: Monitoring of plasma disappearance rate of indocyanine green in a patient with necrotizing fasciitis and septic shock. Dtsch Med Wochenschr 2004, 129: 2590-2593. 10.1055/s-2004-836080CrossRefPubMed Kortgen A, Lindemann W, Bauer M: Monitoring of plasma disappearance rate of indocyanine green in a patient with necrotizing fasciitis and septic shock. Dtsch Med Wochenschr 2004, 129: 2590-2593. 10.1055/s-2004-836080CrossRefPubMed
12.
go back to reference Sakka S, Meier-Hellmann A: Indocyanine green for the assessment of liver function in critically ill patients. In Yearbook of Intensive Care and Emergency Medicine. Edited by: Vincent JL. Berlin: Springer; 2001:611-618. Sakka S, Meier-Hellmann A: Indocyanine green for the assessment of liver function in critically ill patients. In Yearbook of Intensive Care and Emergency Medicine. Edited by: Vincent JL. Berlin: Springer; 2001:611-618.
13.
go back to reference Escorsell A, Mas A, Fernandez J, Garcia-Valdecasas JC: Limitations of use of the noninvasive clearance of indocyanine green as a prognostic indicator of graft function in liver transplantation. Transplant Proc 2012, 44: 1539-1541. 10.1016/j.transproceed.2012.05.023CrossRefPubMed Escorsell A, Mas A, Fernandez J, Garcia-Valdecasas JC: Limitations of use of the noninvasive clearance of indocyanine green as a prognostic indicator of graft function in liver transplantation. Transplant Proc 2012, 44: 1539-1541. 10.1016/j.transproceed.2012.05.023CrossRefPubMed
14.
go back to reference Hunton DB, Bollman JL, Hoffman HN: Studies of hepatic function with indocyanine green. Gastroenterology 1960, 39: 713-724.PubMed Hunton DB, Bollman JL, Hoffman HN: Studies of hepatic function with indocyanine green. Gastroenterology 1960, 39: 713-724.PubMed
15.
go back to reference Stehr A, Ploner F, Traeger K, Theisen M, Zuelke C, Radermacher P, Matejovic M: Plasma disappearance of indocyanine green: a marker for excretory liver function? Intensive Care Med 2005, 31: 1719-1722. 10.1007/s00134-005-2826-7CrossRefPubMed Stehr A, Ploner F, Traeger K, Theisen M, Zuelke C, Radermacher P, Matejovic M: Plasma disappearance of indocyanine green: a marker for excretory liver function? Intensive Care Med 2005, 31: 1719-1722. 10.1007/s00134-005-2826-7CrossRefPubMed
16.
go back to reference Lock JF, Schwabauer E, Martus P, Videv N, Pratschke J, Malinowski M, Neuhaus P, Stockmann M: Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation. Liver Transpl 2010, 16: 172-180. 10.1002/lt.21973CrossRefPubMed Lock JF, Schwabauer E, Martus P, Videv N, Pratschke J, Malinowski M, Neuhaus P, Stockmann M: Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation. Liver Transpl 2010, 16: 172-180. 10.1002/lt.21973CrossRefPubMed
17.
go back to reference Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P: The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010, 12: 139-146. 10.1111/j.1477-2574.2009.00151.xCrossRef Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P: The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010, 12: 139-146. 10.1111/j.1477-2574.2009.00151.xCrossRef
18.
go back to reference Stockmann M, Lock JF, Malinowski M, Seehofer D, Puhl G, Pratschke J, Neuhaus P: How to define initial poor graft function after liver transplantation? A new functional definition by the LiMAx test. Transpl Int 2010, 23: 1023-1032. 10.1111/j.1432-2277.2010.01089.xCrossRefPubMed Stockmann M, Lock JF, Malinowski M, Seehofer D, Puhl G, Pratschke J, Neuhaus P: How to define initial poor graft function after liver transplantation? A new functional definition by the LiMAx test. Transpl Int 2010, 23: 1023-1032. 10.1111/j.1432-2277.2010.01089.xCrossRefPubMed
19.
go back to reference Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, Lehmann S, Niehues SM, Schwabe M, Lemke AJ, Neuhaus P: Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009, 250: 119-125. 10.1097/SLA.0b013e3181ad85b5CrossRefPubMed Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, Lehmann S, Niehues SM, Schwabe M, Lemke AJ, Neuhaus P: Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009, 250: 119-125. 10.1097/SLA.0b013e3181ad85b5CrossRefPubMed
20.
go back to reference Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2001,2003(31):1250-1256. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2001,2003(31):1250-1256.
21.
go back to reference Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41: 580-637. 10.1097/CCM.0b013e31827e83afCrossRefPubMed Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41: 580-637. 10.1097/CCM.0b013e31827e83afCrossRefPubMed
22.
go back to reference Wacharasint P, Nakada TA, Boyd JH, Russell JA, Walley KR: Normal-range blood lactate concentration in septic shock is prognostic and predictive. Shock (Augusta, Ga) 2012, 38: 4-10. 10.1097/SHK.0b013e318254d41aCrossRef Wacharasint P, Nakada TA, Boyd JH, Russell JA, Walley KR: Normal-range blood lactate concentration in septic shock is prognostic and predictive. Shock (Augusta, Ga) 2012, 38: 4-10. 10.1097/SHK.0b013e318254d41aCrossRef
23.
go back to reference Venkataraman R, Kellum JA: Defining acute renal failure: the RIFLE criteria. J Intensive Care Med 2007, 22: 187-193. 10.1177/0885066607299510CrossRefPubMed Venkataraman R, Kellum JA: Defining acute renal failure: the RIFLE criteria. J Intensive Care Med 2007, 22: 187-193. 10.1177/0885066607299510CrossRefPubMed
24.
go back to reference Drews RE, Weinberger SE: Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med 2000, 162: 347-351. 10.1164/ajrccm.162.2.ncc3-00CrossRefPubMed Drews RE, Weinberger SE: Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med 2000, 162: 347-351. 10.1164/ajrccm.162.2.ncc3-00CrossRefPubMed
25.
go back to reference Mochida S, Takikawa Y, Nakayama N, Oketani M, Naiki T, Yamagishi Y, Ichida T, Tsubouchi H: Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 2011, 41: 805-812. 10.1111/j.1872-034X.2011.00860.xCrossRefPubMed Mochida S, Takikawa Y, Nakayama N, Oketani M, Naiki T, Yamagishi Y, Ichida T, Tsubouchi H: Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 2011, 41: 805-812. 10.1111/j.1872-034X.2011.00860.xCrossRefPubMed
26.
go back to reference Polson J, Lee WM: AASLD position paper: the management of acute liver failure. Hepatology 2005, 41: 1179-1197. 10.1002/hep.20703CrossRefPubMed Polson J, Lee WM: AASLD position paper: the management of acute liver failure. Hepatology 2005, 41: 1179-1197. 10.1002/hep.20703CrossRefPubMed
27.
go back to reference Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA: Systematic review: acute liver failure – one disease, more than 40 definitions. Aliment Pharmacol Ther 2012, 35: 1245-1256. 10.1111/j.1365-2036.2012.05097.xCrossRefPubMed Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA: Systematic review: acute liver failure – one disease, more than 40 definitions. Aliment Pharmacol Ther 2012, 35: 1245-1256. 10.1111/j.1365-2036.2012.05097.xCrossRefPubMed
28.
go back to reference Recknagel P, Gonnert FA, Westermann M, Lambeck S, Lupp A, Rudiger A, Dyson A, Carre JE, Kortgen A, Krafft C, Popp J, Sponholz C, Fuhrmann V, Hilger I, Claus RA, Riedemann NC, Wetzker R, Singer M, Trauner M, Bauer M: Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med 2012, 9: e1001338. 10.1371/journal.pmed.1001338PubMedCentralCrossRefPubMed Recknagel P, Gonnert FA, Westermann M, Lambeck S, Lupp A, Rudiger A, Dyson A, Carre JE, Kortgen A, Krafft C, Popp J, Sponholz C, Fuhrmann V, Hilger I, Claus RA, Riedemann NC, Wetzker R, Singer M, Trauner M, Bauer M: Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med 2012, 9: e1001338. 10.1371/journal.pmed.1001338PubMedCentralCrossRefPubMed
29.
go back to reference Inal MT, Memis D, Kargi M, Sut N: Prognostic value of indocyanine green elimination assessed with LiMON in septic patients. J Crit Care 2009, 24: 329-334. 10.1016/j.jcrc.2008.11.012CrossRefPubMed Inal MT, Memis D, Kargi M, Sut N: Prognostic value of indocyanine green elimination assessed with LiMON in septic patients. J Crit Care 2009, 24: 329-334. 10.1016/j.jcrc.2008.11.012CrossRefPubMed
30.
go back to reference Schneider L, Spiegel M, Latanowicz S, Weigand MA, Schmidt J, Werner J, Stremmel W, Eisenbach C: Noninvasive indocyanine green plasma disappearance rate predicts early complications, graft failure or death after liver transplantation. Hepatobiliary Pancreat Dis Int 2011, 10: 362-368. 10.1016/S1499-3872(11)60061-1CrossRefPubMed Schneider L, Spiegel M, Latanowicz S, Weigand MA, Schmidt J, Werner J, Stremmel W, Eisenbach C: Noninvasive indocyanine green plasma disappearance rate predicts early complications, graft failure or death after liver transplantation. Hepatobiliary Pancreat Dis Int 2011, 10: 362-368. 10.1016/S1499-3872(11)60061-1CrossRefPubMed
31.
go back to reference Carcillo JA, Doughty L, Kofos D, Frye RF, Kaplan SS, Sasser H, Burckart GJ: Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003, 29: 980-984.PubMed Carcillo JA, Doughty L, Kofos D, Frye RF, Kaplan SS, Sasser H, Burckart GJ: Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003, 29: 980-984.PubMed
32.
go back to reference Sharpe DA, Mitchel IM, Kay EA, McGoldrick JP, Munsch CM, Kay PH: Enhancing liver blood flow after cardiopulmonary bypass: the effects of dopamine and dopexamine. Perfusion 1999, 14: 29-36. 10.1177/026765919901400105CrossRefPubMed Sharpe DA, Mitchel IM, Kay EA, McGoldrick JP, Munsch CM, Kay PH: Enhancing liver blood flow after cardiopulmonary bypass: the effects of dopamine and dopexamine. Perfusion 1999, 14: 29-36. 10.1177/026765919901400105CrossRefPubMed
33.
go back to reference Heintz R, Svensson CK, Stoeckel K, Powers GJ, Lalka D: Indocyanine green: pharmacokinetics in the rabbit and relevant studies of its stability and purity. J Pharm Sci 1986, 75: 398-402. 10.1002/jps.2600750417CrossRefPubMed Heintz R, Svensson CK, Stoeckel K, Powers GJ, Lalka D: Indocyanine green: pharmacokinetics in the rabbit and relevant studies of its stability and purity. J Pharm Sci 1986, 75: 398-402. 10.1002/jps.2600750417CrossRefPubMed
34.
go back to reference Paumgartner G: The handling of indocyanine green by the liver. Schweiz Med Wochenschr 1975, 105: 1-30.PubMed Paumgartner G: The handling of indocyanine green by the liver. Schweiz Med Wochenschr 1975, 105: 1-30.PubMed
35.
go back to reference Hunton DB, Bollman JL, Hoffman HN 2nd: The plasma removal on indocyanine green and sulfobromophthalein: effect of dosage and blocking agents. J Clin Invest 1961, 40: 1648-1655. 10.1172/JCI104387PubMedCentralCrossRefPubMed Hunton DB, Bollman JL, Hoffman HN 2nd: The plasma removal on indocyanine green and sulfobromophthalein: effect of dosage and blocking agents. J Clin Invest 1961, 40: 1648-1655. 10.1172/JCI104387PubMedCentralCrossRefPubMed
36.
go back to reference Baumgartner U, Scholmerich J, Feuerstein E, Baier P, Ihling C: Repetitive short-term bile duct obstruction and relief causes reproducible and reversible bile acid regurgitation. J Surg Res 2003, 110: 222-227. 10.1016/S0022-4804(02)00082-3CrossRefPubMed Baumgartner U, Scholmerich J, Feuerstein E, Baier P, Ihling C: Repetitive short-term bile duct obstruction and relief causes reproducible and reversible bile acid regurgitation. J Surg Res 2003, 110: 222-227. 10.1016/S0022-4804(02)00082-3CrossRefPubMed
37.
go back to reference Cotting J, Zysset T, Reichen J: Biliary obstruction dissipates bioelectric sinusoidal-canalicular barrier without altering taurocholate uptake. Am J Physiol 1989, 256: G312-G318.PubMed Cotting J, Zysset T, Reichen J: Biliary obstruction dissipates bioelectric sinusoidal-canalicular barrier without altering taurocholate uptake. Am J Physiol 1989, 256: G312-G318.PubMed
38.
go back to reference Fuhrmann V, Jager B, Zubkova A, Drolz A: Hypoxic hepatitis – epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr 2010, 122: 129-139. 10.1007/s00508-010-1357-6CrossRefPubMed Fuhrmann V, Jager B, Zubkova A, Drolz A: Hypoxic hepatitis – epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr 2010, 122: 129-139. 10.1007/s00508-010-1357-6CrossRefPubMed
39.
go back to reference Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Kitzberger R, Warszawska J, Holzinger U, Schenk P, Madl C: Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 2009, 35: 1397-1405. 10.1007/s00134-009-1508-2CrossRefPubMed Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Kitzberger R, Warszawska J, Holzinger U, Schenk P, Madl C: Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 2009, 35: 1397-1405. 10.1007/s00134-009-1508-2CrossRefPubMed
40.
go back to reference Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M: A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009, 35: 717-721. 10.1007/s00134-008-1358-3CrossRefPubMed Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M: A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009, 35: 717-721. 10.1007/s00134-008-1358-3CrossRefPubMed
41.
go back to reference Arundel C, Lewis JH: Drug-induced liver disease in 2006. Curr Opin Gastroenterol 2007, 23: 244-254. 10.1097/MOG.0b013e3280b17dfbCrossRefPubMed Arundel C, Lewis JH: Drug-induced liver disease in 2006. Curr Opin Gastroenterol 2007, 23: 244-254. 10.1097/MOG.0b013e3280b17dfbCrossRefPubMed
42.
go back to reference Sakka SG, van Hout N: Relation between indocyanine green (ICG) plasma disappearance rate and ICG blood clearance in critically ill patients. Intensive Care Med 2006, 32: 766-769. 10.1007/s00134-006-0109-6CrossRefPubMed Sakka SG, van Hout N: Relation between indocyanine green (ICG) plasma disappearance rate and ICG blood clearance in critically ill patients. Intensive Care Med 2006, 32: 766-769. 10.1007/s00134-006-0109-6CrossRefPubMed
Metadata
Title
Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: a prospective study with the LiMAx test
Authors
Magnus F Kaffarnik
Johan F Lock
Hannah Vetter
Navid Ahmadi
Christian Lojewski
Maciej Malinowski
Peter Neuhaus
Martin Stockmann
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Critical Care / Issue 5/2013
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13089

Other articles of this Issue 5/2013

Critical Care 5/2013 Go to the issue